MedTrace Logo

Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

NCT02471820 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-10-17

No results posted yet for this study

Summary

This study is to assess the efficacy and safety of lenalidomide in combination with adriamycin and low dose dexamethasone in newly diagnosed patients with symptomatic multiple myeloma as well as to collect information regarding the effect of this regimen on angiogenesis and bone remodeling of the study population.

Conditions

Interventions

DRUG

Lenalidomide

Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles

DRUG

Adriamycin

Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles

DRUG

Dexamethasone

Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles

Sponsors & Collaborators

  • Meletios A. Dimopoulos

    lead OTHER

Principal Investigators

  • Meletios Dimopoulos, Doctor · General Hospital of Athens "Alexandra"

  • Eirini Katodritou, Doctor · Theageneio Anticancer Hospital of Thessaloniki

  • Nikolaos Anagnostopoulos, Doctor · General Hospital of Athens "G. Gennimatas''

  • Argirios Symeonidis, Doctor · University General Hospital of Patras

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471820 on ClinicalTrials.gov